Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Partner to Expand ADC Manufacturing Capabilities
Event summary
- Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services announced a strategic collaboration on April 16, 2026, to enhance ADC development and manufacturing.
- Piramal will refer customers seeking ADC manufacturing technology to Ajinomoto Bio-Pharma Services and its AJICAP™ technology.
- Ajinomoto Bio-Pharma Services will refer Piramal to customers as a potential CDMO for manufacturing products using AJICAP™ technology.
- A separate Material Transfer Agreement (MTA) will allow the transfer of technology between the companies, equipping Piramal to manufacture AJICAP™-based products.
The big picture
This collaboration combines Piramal's extensive ADC manufacturing expertise with Ajinomoto Bio-Pharma Services' innovative AJICAP™ technology, aiming to streamline the development and commercialization of ADC therapies. The partnership underscores the growing trend of strategic alliances in the biopharmaceutical sector to enhance manufacturing capabilities and accelerate drug development. With ongoing expansions in commercial-scale ADC capacity, Piramal is positioning itself as a key player in the rapidly evolving ADC market.
What we're watching
- Technology Integration
- How quickly Piramal can integrate AJICAP™ technology into its existing ADC manufacturing processes.
- Market Expansion
- Whether the collaboration will accelerate the adoption of AJICAP™ technology among early-stage pharmaceutical developers.
- Competitive Dynamics
- The pace at which other CDMOs respond to this partnership with similar strategic collaborations.
Related topics